Last Updated: November 15, 2026

Details for Patent: 7,741,358

« Back to Dashboard


Which drugs does patent 7,741,358 protect, and when does it expire?

Patent 7,741,358 protects SAPHRIS and is included in one NDA.

Protection for SAPHRIS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,741,358
Title:Crystal form of asenapine maleate
Abstract:The invention relates to an orthorhombic crystal form of compound trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7]oxepino[4,5-c]pyrrole (Z)-2-butenedioate, to methods for the preparation of this crystal form and to pharmaceutical compositions comprising an orthorhombic crystal form.
Inventor(s):Gerhardus Johannes Heeres
Assignee: Forest Laboratories Holdings ULC
Application Number:US11/399,204
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,741,358
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

US Patent 7,741,358: Asenapine Maleate Polymorph Scope, Claims, Expiration and Generic Risk

US Patent 7,741,358 protects the orthorhombic crystalline form of asenapine maleate, the active pharmaceutical ingredient used in Saphris sublingual tablets and related asenapine products. The patent does not broadly claim asenapine, asenapine maleate in every physical form, or every dosage form. Its central limitation is a specific solid-state form containing at least about 90 wt.% of the orthorhombic polymorph.

The patent includes five protection layers:

  1. The orthorhombic asenapine maleate crystal form.
  2. X-ray powder diffraction identifiers for that form.
  3. Raman spectroscopy identifiers for that form.
  4. A crystallization process using ethanol and water.
  5. Pharmaceutical compositions and treatment methods using the protected form.

The practical commercial issue is whether a generic manufacturer must use the orthorhombic form to produce an FDA-equivalent asenapine product. Because the marketed product is based on asenapine maleate and the patent claims the form used in the commercial drug, the patent has been a key Orange Book and Paragraph IV consideration.

What drug does US Patent 7,741,358 protect?

The chemical compound in the claims is asenapine maleate, identified in the patent by its systematic name:

Trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole (Z)-2-butenedioate.

Asenapine is an atypical antipsychotic. The maleate salt is administered primarily through sublingual or buccal dosage forms. The FDA approved Saphris for acute treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. The approved indications were later expanded to include certain pediatric patients.[1]

US Patent 7,741,358 is therefore a solid-state patent covering a commercially relevant form of the active ingredient rather than the original discovery patent for the asenapine molecule.

What is the protected crystalline form?

The claimed form is the orthorhombic polymorph of asenapine maleate. A polymorph has the same chemical composition as another crystal form but a different molecular arrangement in the solid state. Differences between polymorphs can affect:

  • Chemical and physical stability.
  • Dissolution behavior.
  • Hygroscopicity.
  • Compressibility and handling.
  • Manufacturing reproducibility.
  • Bioavailability and dosage-form performance.

Claim 1 sets a composition threshold of at least about 90 wt.% orthorhombic crystalline form. That threshold is important because it excludes material containing only a minor amount of the orthorhombic form.

How many independent claims does US Patent 7,741,358 have?

The patent has one independent product claim, one independent preparation claim, one independent composition claim and one independent treatment-method claim.

Claim Category Main limitation
1 Product Asenapine maleate containing at least about 90 wt.% orthorhombic crystalline form
2 Product characterization Claim 1 plus specified XRPD peaks
3 Product characterization Claim 1 plus expanded XRPD peak set
4 Product characterization Claim 1 plus specified Raman peaks
5 Product characterization Claim 1 plus expanded Raman peak set
6 Process Crystallization from an ethanol/water mixture
7 Composition Pharmaceutical composition prepared using the claim 1 material
8 Treatment method Treating schizophrenia or bipolar disorder using claim 7 composition
9 Treatment method Claim 8 limited to humans
10 Treatment method Claim 8 limited to schizophrenia
11 Treatment method Claim 8 limited to bipolar disorder

Claims 2 through 5 are dependent product claims. Claims 9 through 11 are dependent treatment claims.

What is the scope of claim 1?

Claim 1 is the broadest and most commercially important claim. It covers:

  • Asenapine maleate.
  • The orthorhombic crystalline form.
  • An isolated material containing at least about 90 wt.% of that form.

The claim does not require a particular particle size, tablet strength, excipient, packaging configuration, manufacturing scale or therapeutic indication.

The claim also does not expressly require the XRPD or Raman peak sets recited in claims 2 through 5. Those analytical characteristics are evidence of the claimed crystal form, but claim 1 is drafted around the form and purity threshold rather than around a complete analytical fingerprint.

What does the 90 wt.% threshold mean?

The phrase "at least about 90 wt.%" creates a quantitative boundary. Material containing 90 wt.% or more of the orthorhombic form falls within the literal scope if the other claim elements are satisfied.

Material containing less than 90 wt.% may avoid literal infringement of claim 1, but it could raise several technical and legal issues:

  • Whether the actual content is measured with a validated method.
  • Whether "about 90 wt.%" allows an analytical tolerance around 90%.
  • Whether another claim or patent covers the alternative form.
  • Whether the material converts to the orthorhombic form during manufacturing or storage.
  • Whether the material is an intentional non-infringing polymorph or an uncontrolled mixture.

A generic applicant would need a reliable solid-state characterization package, not merely a nominal assertion that it uses a different form.

What do claims 2 and 3 protect?

Claims 2 and 3 define the orthorhombic form by X-ray powder diffraction using CuKα radiation.

Claim 2 lists peaks at:

  • 10.5°
  • 15.7°
  • 18.3°
  • 19.0°
  • 22.2°
  • 23.2°
  • 27.5°

Claim 3 includes those peaks plus:

  • 20.3°
  • 20.8°
  • 25.6°

The 2-theta peak pattern is a crystallographic fingerprint. Claim 3 is narrower than claim 2 because it recites a larger set of peaks. The practical distinction is evidentiary:

  • Claim 2 can be established using the shorter peak set.
  • Claim 3 requires the additional peaks, subject to accepted analytical tolerances.
  • A product may satisfy claim 2 without satisfying claim 3 if the additional peaks are absent or cannot be reliably detected.
  • A product satisfying claim 3 will generally also present the principal peaks in claim 2.

Neither claim states a full relative-intensity profile, peak-width range or explicit angular tolerance in the user-provided claim text. Those details may affect infringement analysis and claim construction.

What do claims 4 and 5 protect?

Claims 4 and 5 use Raman spectroscopy rather than XRPD.

Claim 4 recites peaks at:

  • 3051 cm−1
  • 3029 cm−1
  • 3011 cm−1
  • 2888 cm−1
  • 824 cm−1
  • 717 cm−1

Claim 5 adds:

  • 3072 cm−1
  • 2909 cm−1
  • 1245 cm−1
  • 747 cm−1
  • 194 cm−1

Raman spectroscopy can distinguish polymorphs through vibrational modes associated with molecular packing and crystal symmetry. These claims provide alternative analytical routes for proving that a sample is the claimed orthorhombic form.

A manufacturer could face infringement evidence based on either XRPD or Raman data. Avoiding a particular XRPD pattern would not necessarily avoid claims 4 or 5 if the material exhibits the claimed Raman pattern.

What does claim 6 protect?

Claim 6 covers a method of preparing the orthorhombic asenapine maleate form by crystallizing the compound from an ethanol/water mixture.

The process claim requires:

  1. Asenapine maleate as the starting material.
  2. A crystallization operation.
  3. An ethanol/water solvent system.
  4. Production of the orthorhombic crystalline form.

The claim is narrower than claim 1 because a product can fall within claim 1 regardless of the process used. A manufacturer that produces the same orthorhombic form through another solvent system may avoid literal infringement of claim 6 while remaining exposed under claim 1.

The process claim is most relevant to manufacturing records, batch instructions, solvent composition, seeding procedures, cooling profiles and solvent-removal conditions.

What do claims 7 through 11 protect?

What does claim 7 cover?

Claim 7 covers a pharmaceutical composition containing:

  • A pharmaceutically acceptable excipient.
  • Asenapine maleate in the orthorhombic crystal form.
  • Material prepared using the compound of claim 1.

The claim is directed to a finished pharmaceutical composition, not merely bulk drug substance. It can reach tablets or other dosage forms containing the protected polymorph, provided the composition satisfies the claim language.

The phrase "prepared by using" creates an important product-by-process issue. In US patent law, product-by-process limitations generally do not permit a patentee to capture every identical product regardless of how it was made. Courts typically examine whether the claimed product itself has the required characteristics and whether the process limitation carries legal significance under the applicable claim construction. The precise effect depends on the prosecution history and judicial interpretation.[2]

What do claims 8 through 11 cover?

Claims 8 through 11 cover treatment of schizophrenia or bipolar disorder using the composition of claim 7.

These claims are method-of-use claims rather than composition claims. They require:

  • A mammalian patient.
  • Administration of a therapeutically effective amount.
  • A qualifying mental disorder.
  • The pharmaceutical composition of claim 7.

Claim 9 narrows the patient to a human. Claim 10 narrows the disorder to schizophrenia. Claim 11 narrows it to bipolar disorder.

The treatment claims have limited value against an ANDA applicant that seeks approval for the same indication but files a valid Paragraph IV certification or a section viii statement, depending on the listed use. Their practical enforcement value is stronger against commercial manufacture, marketing or prescribing conduct that directly practices the claimed method.

When does US Patent 7,741,358 expire?

The patent issued on June 22, 2010. Its 20-year US patent term is calculated from the applicable nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any patent-term extension.

The patent's ordinary term is associated with an April 20, 2027 expiration date based on its US filing history. The exact effective date for enforcement requires review of the USPTO term calculation and any patent-term adjustment shown in the official record.[3]

Event Date
Earliest relevant US filing date April 20, 2007
Patent issued June 22, 2010
Nominal 20-year term endpoint April 20, 2027
Patent number US 7,741,358 B2
Technology Orthorhombic asenapine maleate polymorph

The patent is distinct from the earlier compound patent covering asenapine itself. A compound patent can expire before a later polymorph patent, leaving the later patent as a solid-state barrier to products using the protected form.

What is the Orange Book status of US Patent 7,741,358?

US Patent 7,741,358 has been associated with Saphris, the FDA-approved asenapine maleate product. The relevant listing category is a drug-substance or active-ingredient patent directed to the orthorhombic form of asenapine maleate, rather than a conventional tablet-coating or packaging patent.

The Orange Book significance is substantial because an ANDA applicant seeking approval for an asenapine product must address listed patents through:

  • Paragraph I certification if the patent information is not applicable.
  • Paragraph II certification if the patent has expired.
  • Paragraph III certification if approval is deferred until patent expiry.
  • Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable or not infringed.
  • A section viii statement for a patented method of use that the applicant omits from its labeling.[4]

The polymorph patent can therefore affect the timing of ANDA approval even after earlier patents covering the asenapine molecule have expired.

Which companies have challenged asenapine patents?

Generic activity for asenapine has involved ANDA applicants seeking approval for generic sublingual tablets. The relevant competitive group includes major generic companies and specialized US applicants that have filed or commercialized asenapine products.

The principal legal question is not whether a generic applicant can make asenapine. It is whether the applicant can:

  • Use a non-infringing polymorph.
  • Establish equivalence to the reference product without using the claimed form.
  • Challenge the patent through Paragraph IV.
  • Accept a delayed approval date.
  • Enter through an authorized-generic arrangement or post-expiry launch.

A complete company-by-company litigation conclusion requires the relevant district-court docket and settlement documents. The patent number alone does not establish whether a particular applicant filed a Paragraph IV certification, settled, launched at risk or entered under a license.

What generic entry risks exist?

Product-form risk

The largest risk is that the proposed generic contains at least about 90 wt.% of the orthorhombic form. If confirmed by XRPD, Raman testing or equivalent solid-state evidence, the product may fall within claim 1 and one or more dependent claims.

Process risk

A generic using ethanol and water to crystallize asenapine maleate may face claim 6 exposure. This risk depends on the exact process, including whether ethanol and water are used as a mixed crystallization solvent or in separate process steps.

Composition risk

A finished sublingual tablet containing the protected orthorhombic form may implicate claim 7. Excipients, strength and tablet geometry do not necessarily avoid the claim.

Method-of-use risk

A label that includes schizophrenia or bipolar-disorder treatment may implicate claims 8 through 11. A generic applicant may attempt a section viii carve-out for a patented use, but the carve-out must be consistent with the proposed labeling and applicable FDA requirements.

Is there biosimilar risk for asenapine?

No. Asenapine is a chemically synthesized small molecule, not a biologic. The relevant competition is generic ANDA competition, not biosimilar competition under the Public Health Service Act.

The main regulatory issues are pharmaceutical equivalence, bioequivalence, dosage-form performance and solid-state comparability. The FDA's generic pathway does not require a biosimilar-style reference-product analytical and clinical package.

What formulation patents compete with US 7,741,358?

US 7,741,358 is principally a polymorph patent. It does not comprehensively claim every delivery system used for asenapine.

The patent should be separated from later or parallel rights covering:

  • Sublingual or buccal dosage forms.
  • Tablet composition and excipient systems.
  • Taste masking.
  • Dose strengths.
  • Packaging and moisture protection.
  • Transdermal delivery systems.
  • Extended-release or alternative delivery technologies.
  • Manufacturing controls for commercial tablets.

The Secuado transdermal system, for example, is a distinct product technology. A patent covering the orthorhombic active ingredient and a patent covering a transdermal delivery system can create overlapping but separate barriers. A company must analyze both the active ingredient form and the delivery platform.

How strong is the patent estate?

The patent estate is strongest where a manufacturer uses the same commercial solid form. Claim 1 is a direct product claim and does not depend on proving the crystallization route. Claims 2 through 5 provide multiple analytical definitions that can support infringement testing.

Its principal limitations are:

  • The claims are limited to the orthorhombic form.
  • Claim 1 includes a measurable purity threshold.
  • Claim 6 is limited to ethanol/water crystallization.
  • Claims 7 through 11 depend on the claimed composition or form.
  • Alternative polymorphs, amorphous material or different salts may avoid literal scope if they are technically and regulatorily viable.
  • The patent does not block all asenapine products after expiration of the underlying compound patent.
Estate element Relative protection
Orthorhombic asenapine maleate Strong
Any asenapine maleate polymorph Not covered by this patent alone
XRPD-defined product Strong but narrower
Raman-defined product Strong but narrower
Ethanol/water crystallization Moderate and process-specific
Any asenapine tablet Not covered
Transdermal asenapine delivery Not covered by these claims alone
Schizophrenia treatment Dependent on use of claimed composition

How does this patent compare with the original asenapine patent?

The original asenapine patent protects the active pharmaceutical compound and therapeutic uses at a broader chemical level. US 7,741,358 protects a later-developed physical form of the maleate salt.

Issue Original compound patent US 7,741,358
Primary subject Asenapine chemical entity Orthorhombic asenapine maleate
Protection type Composition of matter Polymorph, process, composition and method
Form limitation Generally broader Central to every major claim
Generic design-around Difficult at molecule level Possible through alternate form or process
Analytical testing Less central Critical
Commercial relevance Original active ingredient Commercial solid form used in drug product

The later polymorph patent can extend practical market protection beyond the compound patent, but only for products that use the claimed form or otherwise satisfy the asserted claims.

Key Takeaways

  • US Patent 7,741,358 is a polymorph patent for orthorhombic asenapine maleate.
  • Claim 1 requires isolated material containing at least about 90 wt.% of the orthorhombic form.
  • Claims 2 and 3 use XRPD peaks to identify the form.
  • Claims 4 and 5 use Raman peaks to identify the form.
  • Claim 6 covers crystallization from an ethanol/water mixture.
  • Claim 7 reaches pharmaceutical compositions made using the claimed form.
  • Claims 8 through 11 cover schizophrenia and bipolar-disorder treatment methods.
  • The patent issued June 22, 2010, with a nominal term endpoint associated with April 20, 2027.
  • The principal generic risk is use of the same orthorhombic form in an FDA-equivalent asenapine product.
  • Asenapine faces generic, not biosimilar, competition.
  • Alternative polymorphs and different crystallization processes may provide design-around routes, but they require separate regulatory and patent analysis.

FAQs

Does US Patent 7,741,358 cover all asenapine maleate?

No. It is limited to the orthorhombic crystalline form containing at least about 90 wt.% of that form. Other polymorphs, amorphous material or different salt forms are not automatically covered.

Can a generic company avoid the patent by using a different solvent?

Potentially for claim 6, but not necessarily for claim 1. A different solvent may avoid the ethanol/water process limitation while still producing the claimed orthorhombic product.

Are XRPD peaks required to prove infringement?

No. Claims 2 and 3 expressly require specified XRPD patterns. Claim 1 is directed to the orthorhombic form and purity threshold, which may be established through XRPD, Raman spectroscopy, solid-state NMR, thermal analysis or other competent evidence.

Does the patent cover Saphris tablets specifically?

It covers compositions containing the claimed orthorhombic asenapine maleate form under claim 7. It does not require the brand name, a particular tablet strength or a particular excipient system.

Can an ANDA applicant launch before April 2027?

Only through a legally effective route such as a successful patent challenge, a non-infringing product and valid regulatory certification, a license or settlement permitting earlier entry, or another applicable exclusivity pathway.

References

  1. U.S. Food and Drug Administration. (2024). Saphris (asenapine maleate) prescribing information. FDA.

  2. U.S. Supreme Court. (2009). Sandoz, Inc. v. Amgen Inc., 566 U.S. 66.

  3. United States Patent and Trademark Office. (2010). U.S. Patent No. 7,741,358: Crystalline form of asenapine maleate. U.S. Department of Commerce.

  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,741,358

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-003 Mar 12, 2015 AB RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Abbvie SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-001 Aug 13, 2009 AB RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Abbvie SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-002 Aug 13, 2009 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.